SABELUZOLE

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H26FN3O2S
Molecular Weight	415.524
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C1CCN(CC(O)COC2=CC=C(F)C=C2)CC1)C3=NC4=CC=CC=C4S3

InChI

InChIKey=IGMKTIJBFUMVIN-UHFFFAOYSA-N

InChI=1S/C22H26FN3O2S/c1-25(22-24-20-4-2-3-5-21(20)29-22)17-10-12-26(13-11-17)14-18(27)15-28-19-8-6-16(23)7-9-19/h2-9,17-18,27H,10-15H2,1H3

HIDE SMILES / InChI

Molecular Formula	C22H26FN3O2S
Molecular Weight	415.524
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3126527 | https://www.ncbi.nlm.nih.gov/pubmed/8458392 | https://www.ncbi.nlm.nih.gov/pubmed/1336292 | https://www.ncbi.nlm.nih.gov/pubmed/8776785

Sabeluzole (previously known as R 58 735) was developed for the treatment of Alzheimer's disease. It reached phase II clinical trials in Canada and Belgium before its development was discontinued. This drug possibly acts as N-methyl-D-aspartate (NMDA) receptor antagonist. In addition, the effect of sabeluzole on sleep, breathing and daytime symptoms was investigated in 13 patients with obstructive sleep apnea. Besides, no beneficial effect of sabeluzole was shown on peripheral nerve function in patients at an early stage of diabetic polyneuropathy.

Approval Year

PubMed

Title	Date	PubMed
The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease.	2001 Apr-Jun	11391090
Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers.	2001 Feb	11259989
APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.	2001 Mar-Apr	11173877
Preparation and physicochemical characterization of biodegradable nerve guides containing the nerve growth agent sabeluzole.	2005 Apr	15475061
Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis.	2005 Jan-Mar	15764869
Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.	2007 Jun	17451614

Patents

Sample Use Guides

In Vivo Use Guide

5 mg b.i.d. for 2 days followed by 10 mg b.i.d. for 5 days

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:46:53 GMT 2023` Edited by `admin` on `Fri Dec 15 15:46:53 GMT 2023`
Record UNII	A998504XY4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SABELUZOLE

Official Name

English

SABELUZOLE [USAN]

Common Name

English

SABELUZOLE [MART.]

Common Name

English

(±)-4-(2-BENZOTHIAZOLYLMETHYLAMINO)-.ALPHA.-((P-FLUOROPHENOXY)METHYL)-1-PIPERIDINEETHANOL

Common Name

English

Sabeluzole [WHO-DD]

Common Name

English

R-58735

Code

English

SABELUZOLE [MI]

Common Name

English

R 58735

Code

English

sabeluzole [INN]

Common Name

English

1-PIPERIDINEETHANOL, 4-(2-BENZOTHIAZOLYLMETHYLAMINO)-.ALPHA.-((4-FLUOROPHENOXY)METHYL)-

Systematic Name

English

1-PIPERIDINEETHANOL, 4-(2-BENZOTHIAZOLYLMETHYLAMINO)-.ALPHA.-((4-FLUOROPHENOXY)METHYL)-, (±)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1509